{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:50:21Z","timestamp":1777603821931,"version":"3.51.4"},"reference-count":229,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The field of nanomedicine has significantly influenced research areas such as drug delivery, diagnostics, theranostics, and regenerative medicine; however, the further development of this field will face significant challenges at the regulatory level if related guidance remains unclear and unconsolidated. This review describes those features and pathways crucial to the clinical translation of nanomedicine and highlights considerations for early-stage product development. These include identifying those critical quality attributes of the drug product essential for activity and safety, appropriate analytical methods (physical, chemical, biological) for characterization, important process parameters, and adequate pre-clinical models. Additional concerns include the evaluation of batch-to-batch consistency and considerations regarding scaling up that will ensure a successful reproducible manufacturing process. Furthermore, we advise close collaboration with regulatory agencies from the early stages of development to assure an aligned position to accelerate the development of future nanomedicines.<\/jats:p><jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s13346-021-01024-2","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T18:02:51Z","timestamp":1627063371000},"page":"500-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":432,"title":["Current hurdles to the translation of nanomedicines from bench to the clinic"],"prefix":"10.1007","volume":"12","author":[{"given":"Sne\u017eana","family":"\u0110or\u0111evi\u0107","sequence":"first","affiliation":[]},{"given":"Mar\u00eda Medel","family":"Gonzalez","sequence":"additional","affiliation":[]},{"given":"Inmaculada","family":"Conejos-S\u00e1nchez","sequence":"additional","affiliation":[]},{"given":"Barbara","family":"Carreira","sequence":"additional","affiliation":[]},{"given":"Sabina","family":"Pozzi","sequence":"additional","affiliation":[]},{"given":"Rita C.","family":"Ac\u00farcio","sequence":"additional","affiliation":[]},{"given":"Ronit","family":"Satchi-Fainaro","sequence":"additional","affiliation":[]},{"given":"Helena F.","family":"Florindo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7771-3373","authenticated-orcid":false,"given":"Mar\u00eda J.","family":"Vicent","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"1024_CR1","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.2174\/138161210791208992","volume":"16","author":"M Kumar Teli","year":"2010","unstructured":"Kumar Teli M, Mutalik S, Rajanikant GK. Nanotechnology and nanomedicine: going small means aiming big. Curr Pharm Des. 2010;16:1882\u201392. https:\/\/doi.org\/10.2174\/138161210791208992.","journal-title":"Curr Pharm Des"},{"key":"1024_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fphar.2018.00027","volume":"9","author":"L Kou","year":"2018","unstructured":"Kou L, Bhutia YD, Yao Q, He Z, Sun J, Ganapathy V. Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types. Front Pharmacol. 2018;9:27. https:\/\/doi.org\/10.3389\/fphar.2018.00027.","journal-title":"Front Pharmacol"},{"key":"1024_CR3","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941\u201351. https:\/\/doi.org\/10.1038\/nbt.3330.","journal-title":"Nat Biotechnol"},{"key":"1024_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1416","volume":"9","author":"JM Caster","year":"2017","unstructured":"Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology. 2017;9: e1416. https:\/\/doi.org\/10.1002\/wnan.1416.","journal-title":"Wiley Interdiscip Rev Nanomedicine Nanobiotechnology"},{"key":"1024_CR5","doi-asserted-by":"publisher","unstructured":"Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, et al. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 2016;8:325ra17. https:\/\/doi.org\/10.1126\/scitranslmed.aad2355","DOI":"10.1126\/scitranslmed.aad2355"},{"key":"1024_CR6","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1073\/pnas.0601755103","volume":"103","author":"OC Farokhzad","year":"2006","unstructured":"Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103:6315\u201320. https:\/\/doi.org\/10.1073\/pnas.0601755103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1024_CR7","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1038\/s41467-018-04315-4","volume":"9","author":"FC Lam","year":"2018","unstructured":"Lam FC, Morton SW, Wyckoff J, Vu Han TL, Hwang MK, Maffa A, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 2018;9:1991. https:\/\/doi.org\/10.1038\/s41467-018-04315-4.","journal-title":"Nat Commun"},{"key":"1024_CR8","doi-asserted-by":"publisher","unstructured":"Milane L, Amiji M. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Deliv Transl Res. 2021;1\u20137. https:\/\/doi.org\/10.1007\/s13346-021-00911-y","DOI":"10.1007\/s13346-021-00911-y"},{"key":"1024_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines8040649","volume":"8","author":"S Jain","year":"2020","unstructured":"Jain S, Batra H, Yadav P, Chand S. Covid-19 vaccines currently under preclinical and clinical studies, and associated antiviral immune response. Vaccines. 2020;8:1\u201316. https:\/\/doi.org\/10.3390\/vaccines8040649.","journal-title":"Vaccines"},{"key":"1024_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41582-018-0065-0","volume":"14","author":"H Wood","year":"2018","unstructured":"Wood H. FDA approves patisiran to treat hereditary transthyretin amyloidosis. Nat Rev Neurol. 2018;14:570. https:\/\/doi.org\/10.1038\/s41582-018-0065-0.","journal-title":"Nat Rev Neurol"},{"key":"1024_CR11","unstructured":"Committee for Medicinal Products for Human Use (CHMP); Onpattro CHMP Assessment report [Internet]. 2018 [accessed 2021 Mar 30]. p. 1\u2013188. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/onpattro-epar-public-assessment-report_.pdf"},{"key":"1024_CR12","unstructured":"Alnylam Pharmaceuticals I. ONPATTRO \u00ae (patisiran) Product fact sheet [Internet]. 2020 [accessed 2021 Apr 6]. https:\/\/www.alnylam.com\/wp-content\/uploads\/pdfs\/ONPATTRO-Fact-Sheet.pdf"},{"key":"1024_CR13","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.bbrc.2015.08.023","volume":"468","author":"V Sainz","year":"2015","unstructured":"Sainz V, Conniot J, Matos AI, Peres C, Zupan\u010di\u010d E, Moura L, et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015;468:504\u201310. https:\/\/doi.org\/10.1016\/j.bbrc.2015.08.023.","journal-title":"Biochem Biophys Res Commun"},{"key":"1024_CR14","doi-asserted-by":"publisher","unstructured":"Bawa R, Audette GF, Reese BE. Handbook of clinical nanomedicine: law, business, regulation, safety, and risk [Internet]. 1st ed. Bawa R, Audette GF, Reese BE, editors. Handb. Clin. Nanomedicine Law, Business, Regul. Safety, Risk. 2016. https:\/\/doi.org\/10.4032\/9789814669238","DOI":"10.4032\/9789814669238"},{"key":"1024_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2174\/156720111795256156","volume":"8","author":"R Bawa","year":"2012","unstructured":"Bawa R. Regulating nanomedicine\u2014can the FDA Handle It? Curr Drug Deliv. 2012;8:227\u201334. https:\/\/doi.org\/10.2174\/156720111795256156.","journal-title":"Curr Drug Deliv"},{"key":"1024_CR16","unstructured":"Kelly B. Nanomedicines: regulatory challenges and risks ahead [Internet]. 2010 [accessed 2021 Mar 30]. p. 14\u20137. https:\/\/www.cov.com\/-\/media\/files\/corporate\/publications\/2010\/10\/nanomedicinesregulatory.pdf"},{"key":"1024_CR17","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1039\/d0bm00558d","volume":"8","author":"R Foulkes","year":"2020","unstructured":"Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives. Biomater Sci. 2020;8:4653\u201364. https:\/\/doi.org\/10.1039\/d0bm00558d.","journal-title":"Biomater Sci"},{"key":"1024_CR18","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.2174\/1381612825666190117094250","volume":"24","author":"A Sarwal","year":"2019","unstructured":"Sarwal A, Singh G, Singh K, Garg S. Recent interventions for nanotechnology based drug products: insights into the regulatory aspects. Curr Pharm Des. 2019;24:5219\u201328. https:\/\/doi.org\/10.2174\/1381612825666190117094250.","journal-title":"Curr Pharm Des"},{"key":"1024_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.104885","volume":"122","author":"J Allan","year":"2021","unstructured":"Allan J, Belz S, Hoeveler A, Hugas M, Okuda H, Patri A, et al. Regulatory landscape of nanotechnology and nanoplastics from a global perspective. Regul Toxicol Pharmacol. 2021;122: 104885. https:\/\/doi.org\/10.1016\/j.yrtph.2021.104885.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1024_CR20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41565-019-0523-x","volume":"14","author":"HS Leong","year":"2019","unstructured":"Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Duf\u00e8s C, et al. On the issue of transparency and reproducibility in nanomedicine. Nat Nanotechnol. 2019;14:811. https:\/\/doi.org\/10.1038\/s41565-019-0523-x.","journal-title":"Nat Nanotechnol"},{"key":"1024_CR21","doi-asserted-by":"crossref","unstructured":"Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem. Frontiers Media S.A.; 2018;6.","DOI":"10.3389\/fchem.2018.00360"},{"key":"1024_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2217\/nnm-2017-0039","volume":"12","author":"V Agrahari","year":"2017","unstructured":"Agrahari V, Hiremath P. Challenges associated and approaches for successful translation of nanomedicines into commercial products. Nanomedicine. 2017;12:819\u201323. https:\/\/doi.org\/10.2217\/nnm-2017-0039.","journal-title":"Nanomedicine"},{"key":"1024_CR23","doi-asserted-by":"publisher","unstructured":"Limaye V, Fortwengel G, Limaye D. Regulatory roadmap for nanotechnology based medicines. Int J Drug Regul Aff. 2018;2:33\u201341. https:\/\/doi.org\/10.22270\/ijdra.v2i4.151","DOI":"10.22270\/ijdra.v2i4.151"},{"key":"1024_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2217\/nnm.12.3","volume":"7","author":"MS Muthu","year":"2012","unstructured":"Muthu MS, Wilson B. Challenges posed by the scale-up of nanomedicines. Nanomedicine. 2012;7:307\u20139. https:\/\/doi.org\/10.2217\/nnm.12.3.","journal-title":"Nanomedicine"},{"key":"1024_CR25","doi-asserted-by":"publisher","unstructured":"M\u00fchlebach S. Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach? Adv Drug Deliv Rev. 2018;131:122\u201331. https:\/\/doi.org\/10.1016\/j.addr.2018.06.024","DOI":"10.1016\/j.addr.2018.06.024"},{"key":"1024_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/amajethics.2019.347","volume":"21","author":"J Paradise","year":"2019","unstructured":"Paradise J. Regulating nanomedicine at the food and drug administration. AMA J Ethics. 2019;21:347\u201355. https:\/\/doi.org\/10.1001\/amajethics.2019.347.","journal-title":"AMA J Ethics"},{"key":"1024_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/adt.2014.573","volume":"12","author":"R Edmondson","year":"2014","unstructured":"Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12:207\u201318. https:\/\/doi.org\/10.1089\/adt.2014.573.","journal-title":"Assay Drug Dev Technol"},{"key":"1024_CR28","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.bioactmat.2020.09.022","volume":"6","author":"X Chen","year":"2021","unstructured":"Chen X, Zhang YS, Zhang X, Liu C. Organ-on-a-chip platforms for accelerating the evaluation of nanomedicine. Bioact Mater. 2021;6:1012\u201327. https:\/\/doi.org\/10.1016\/j.bioactmat.2020.09.022.","journal-title":"Bioact Mater"},{"key":"1024_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejps.2018.11.019","volume":"128","author":"B Fl\u00fchmann","year":"2019","unstructured":"Fl\u00fchmann B, Ntai I, Borchard G, Simoens S, M\u00fchlebach S. Nanomedicines: the magic bullets reaching their target? Eur J Pharm Sci. 2019;128:73\u201380. https:\/\/doi.org\/10.1016\/j.ejps.2018.11.019.","journal-title":"Eur J Pharm Sci"},{"key":"1024_CR30","doi-asserted-by":"publisher","unstructured":"Gaur N, Sharma N, Dahiya A, Yadav P, Ojha H, Goyal RK, et al. Toxicity and regulatory concerns for nanoformulations in medicine. ELSI Handb Nanotechnol. 2020. p. 333\u201357. https:\/\/doi.org\/10.1002\/9781119592990.ch13","DOI":"10.1002\/9781119592990.ch13"},{"key":"1024_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/2211738505666171023152928","volume":"6","author":"MA Saifi","year":"2018","unstructured":"Saifi MA, Khan W, Godugu C. Cytotoxicity of nanomaterials: using nanotoxicology to address the safety concerns of nanoparticles. Pharm Nanotechnol. 2018;6:3\u201316. https:\/\/doi.org\/10.2174\/2211738505666171023152928.","journal-title":"Pharm Nanotechnol"},{"key":"1024_CR32","doi-asserted-by":"publisher","unstructured":"Sharma HS, Hussain S, Schlager J, Ali SF, Sharma A. Influence of nanoparticles on blood-brain barrier permeability and brain edema formation in rats. Acta Neurochir Suppl. 2009. p. 359\u201364. https:\/\/doi.org\/10.1007\/978-3-211-98811-4_65","DOI":"10.1007\/978-3-211-98811-4_65"},{"key":"1024_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/17435390.2018.1505000","volume":"13","author":"S Siegrist","year":"2019","unstructured":"Siegrist S, C\u00f6rek E, Detampel P, Sandstr\u00f6m J, Wick P, Huwyler J. Preclinical hazard evaluation strategy for nanomedicines. Nanotoxicology. 2019;13:73\u201399. https:\/\/doi.org\/10.1080\/17435390.2018.1505000.","journal-title":"Nanotoxicology"},{"key":"1024_CR34","doi-asserted-by":"publisher","unstructured":"Bohara RA, Thorat N. Hybrid nanostructures for cancer theranostics. Elsevier; 2018;1\u2013262. https:\/\/doi.org\/10.1016\/c2017-0-00466-4","DOI":"10.1016\/c2017-0-00466-4"},{"key":"1024_CR35","unstructured":"EU. Commission Reccomendation of 18 October 2011 on the definition of nanomaterial. Off J Eur Union. 2011 [accessed 2021 Mar 12];L275:338\u201340. https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2011:275:0038:0040:en:PDF"},{"key":"1024_CR36","unstructured":"European Medicines Agency (EMA). Multidisciplinary: nanomedicines | European Medicines Agency. [accessed 2021 Mar 21]; https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/scientific-guidelines\/multidisciplinary\/multidisciplinary-nanomedicines"},{"key":"1024_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/wnan.1531","volume":"11","author":"B Halamoda-Kenzaoui","year":"2019","unstructured":"Halamoda-Kenzaoui B, Holzwarth U, Roebben G, Bogni A, Bremer-Hoffmann S. Mapping of the available standards against the regulatory needs for nanomedicines. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology. 2019;11:1\u201317. https:\/\/doi.org\/10.1002\/wnan.1531.","journal-title":"Wiley Interdiscip Rev Nanomedicine Nanobiotechnology"},{"key":"1024_CR38","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1208\/s12248-016-9967-1","volume":"18","author":"R Pita","year":"2016","unstructured":"Pita R, Ehmann F, Papaluca M. Nanomedicines in the EU\u2014regulatory overview. AAPS J. 2016;18:1576\u201382. https:\/\/doi.org\/10.1208\/s12248-016-9967-1.","journal-title":"AAPS J"},{"key":"1024_CR39","doi-asserted-by":"publisher","unstructured":"Rauscher H, Roebben G, Rauscher H, Roebben G, Sanfeliu AB, Emons H, et al. Towards a review of the EC Recommendation for a definition of the term \u201cnanomaterial\u201d Part 3. Luxemburg; 2015;34. https:\/\/doi.org\/10.2788\/678452","DOI":"10.2788\/678452"},{"key":"1024_CR40","doi-asserted-by":"publisher","unstructured":"Rauscher H, Roebben G, Amenta V, Sanfeliu AB, Calzolai L, Emons H, et al. Towards a review of the EC Recommendation for a definition of the term \u201cnanomaterial\u201d Part 2. Luxemb Publ Off Eur Union. Luxemburg; 2014; https:\/\/doi.org\/10.2787\/97286","DOI":"10.2787\/97286"},{"key":"1024_CR41","doi-asserted-by":"publisher","unstructured":"Rauscher H, Roebben G, Amenta V, Boix Sanfeliu A, Calzolai L, Emons H, et al. Towards a review of the EC Recommendation for a definition of the term \u201cnanomaterial\u201d; Part 1: Compilation of information concerning the experience with the definition. 2014; https:\/\/doi.org\/10.2788\/36237","DOI":"10.2788\/36237"},{"key":"1024_CR42","unstructured":"European Commission. Regulation (EC) No 1907\/2006\u2014Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). 2006 [accessed 2021 Mar 27]; https:\/\/osha.europa.eu\/pt\/legislation\/directives\/regulation-ec-no-1907-2006-of-the-european-parliament-and-of-the-council"},{"key":"1024_CR43","unstructured":"European Chemicals Agency (ECHA). Nanomateriais\u2014ECHA. 2020 [accessed 2021 Mar 27]; https:\/\/echa.europa.eu\/pt\/regulations\/nanomaterials"},{"key":"1024_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2903\/j.efsa.2009.958\/epdf","volume":"13","author":"R Schoonjans","year":"2016","unstructured":"Schoonjans R. Annual report of the EFSA Scientific network of risk assessment of nanotechnologies in food and feed for 2016. EFSA Support Publ. 2016;13:1\u201339. https:\/\/doi.org\/10.2903\/j.efsa.2009.958\/epdf.","journal-title":"EFSA Support Publ"},{"key":"1024_CR45","doi-asserted-by":"publisher","unstructured":"Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S, et al. Guidance on risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain: Part 1, human and animal health. EFSA J. 2018;16. https:\/\/doi.org\/10.2903\/j.efsa.2018.5327","DOI":"10.2903\/j.efsa.2018.5327"},{"key":"1024_CR46","unstructured":"Food and Drug Administration (FDA). Guidance for industry assessing the effects of significant manufacturing process changes, including emerging technologies, on the safety and regulatory status of food ingredients and food contact substances, including F. 2014; https:\/\/www.fda.gov\/media\/115075\/download"},{"key":"1024_CR47","unstructured":"Food and Drug Administration (FDA). Guidance for Industry Safety of Nanomaterials in Cosmetic Products. 2014; https:\/\/www.fda.gov\/media\/83957\/download"},{"key":"1024_CR48","unstructured":"FDA. Guidance for industry use of nanomaterials in food for animals. 2015; https:\/\/www.fda.gov\/media\/88828\/download"},{"key":"1024_CR49","unstructured":"Food and Drug Administration (FDA). Nanotechnology programs at FDA | FDA. [accessed 2021 Mar 27]; https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/nanotechnology-programs-fda"},{"key":"1024_CR50","doi-asserted-by":"publisher","unstructured":"Borgos SE. Joining transatlantic forces via the EU-US communities of research and the EU-NCL. Private communication at global Summit on regulatory science 2019 on nanotechnology and nanoplastics. 2019; https:\/\/doi.org\/10.2760\/517689","DOI":"10.2760\/517689"},{"key":"1024_CR51","unstructured":"Jacqueline A, Birgit SK, Anil P. Global summit on regulatory science 2019 Nanotechnology and Nanoplastics. 2929."},{"key":"1024_CR52","unstructured":"US Food and Drug Administration. Guidance for industry: liposome drug products\u2014chemistry manufacturing and controls, human pharmacokinetics and bioavailability. Fed Regist. 2002; https:\/\/www.fda.gov\/media\/70837\/download"},{"key":"1024_CR53","unstructured":"Tyner K. Regulatory research supporting the development of drug products containing nanomaterials: a US-FDA perspective. Private Communication at Global Summit on Regulatory Science 2019 on Nanotechnology and Nanoplastics. 2019; https:\/\/www.fda.gov\/files\/drugs\/published\/Drug-Products--Including-Biological-Products--that-Contain-Nanomaterials---Guidance-for-Industry.pdf"},{"key":"1024_CR54","unstructured":"Organisation for Economic Co-operation and Development (OCDE). Publications in the Series on the Safety of Manufactured Nanomaterials - OECD [Internet]. [accessed 2021 Mar 27]. https:\/\/www.oecd.org\/sti\/emerging-tech\/ %0A[accessed on 2021\u201303\u201327]%0A"},{"key":"1024_CR55","unstructured":"Organisation for Economic Co-operation and Development (OCDE). Emerging technologies - OECD [Internet]. [accessed 2021 Mar 27]. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/nanotechnology-based-health-products-food.html"},{"key":"1024_CR56","unstructured":"Health Canada. Nanotechnology-based health products and food - Canada.ca [Internet]. [accessed 2021 Mar 27]. https:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-nanomedicines-current-initiatives-canada-duc-vu-health-canada_en.pdf"},{"key":"1024_CR57","unstructured":"Vu D, Gallivan J. Current issues with nanomedicines in Canada. 2010 [accessed 2021 Mar 27]; https:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-nanomedicines-current-initiatives-canada-duc-vu-health-canada_en.pdf"},{"key":"1024_CR58","unstructured":"Dinda A. Challanges in the development of an Idian guideline for nanopharmaceuticals. Private communication at global Summit on regulatory science 2019 on nanotechnology and nanoplastics. 2019 [accessed 2021 Mar 27]; http:\/\/dbtindia.gov.in\/sites\/default\/files\/uploadfiles\/Guidelines_For_Evaluation_of_Nanopharmaceuticals_in_India_24.10.19.pdf"},{"key":"1024_CR59","doi-asserted-by":"publisher","unstructured":"M. J. The IPRP Nanomedicines Working Group: current and potential future activities. Private communication at global Summit on regulatory science 2019 on nanotechnology and nanoplastics. EUR 30195 EN. 2019; https:\/\/doi.org\/10.2760\/517689","DOI":"10.2760\/517689"},{"key":"1024_CR60","doi-asserted-by":"publisher","unstructured":"Gaspar RS, Florindo HF, Silva LC, Videira MA, Corvo ML, Martins BF, et al. Regulatory aspects of oncologicals: nanosystems main challenges. Springer, Cham; 2014;425\u201352. https:\/\/doi.org\/10.1007\/978-3-319-08084-0_15","DOI":"10.1007\/978-3-319-08084-0_15"},{"key":"1024_CR61","unstructured":"Development of block-copolymer-micelle medicinal products Share [Internet]. https:\/\/www.ema.europa.eu\/en\/development-block-copolymer-micelle-medicinal-products"},{"key":"1024_CR62","unstructured":"EMA. ICH Q7 Good manufacturing practice guidance for active pharmaceutical ingredients guidance for industry. 2016;"},{"key":"1024_CR63","unstructured":"Global API Management Market Will Reach USD 3,436.16 Million by 2022: Zion Market Research. [accessed 2021 Apr 3]; https:\/\/www.globenewswire.com\/news-release\/2017\/07\/27\/1063532\/0\/en\/Global-API-Management-Market-Will-Reach-USD-3-436-16-Million-by-2022-Zion-Market-Research.html"},{"key":"1024_CR64","doi-asserted-by":"publisher","unstructured":"Ehmann F, Sakai-Kato K, Duncan R, P\u00e9rez de la Ossa DH, Pita R, Vidal J-MM, et al. Next-generation nanomedicines and nanosimilars: EU regulators\u2019 initiatives relating to the development and evaluation of nanomedicines. Nanomedicine. Future Medicine Ltd.; 2013;8:849\u201356. https:\/\/doi.org\/10.2217\/nnm.13.68","DOI":"10.2217\/nnm.13.68"},{"key":"1024_CR65","doi-asserted-by":"publisher","unstructured":"Crommelin DJA, Metselaar JM, Storm G. Non-biological complex drugs. AAPS Adv Pharm Sci Ser. 2015;20:77\u2013106. https:\/\/doi.org\/10.1007\/978-3-319-16241-6_3","DOI":"10.1007\/978-3-319-16241-6_3"},{"key":"1024_CR66","unstructured":"ICH guideline impurities in new drug substances Q3A(R2). 2006;"},{"key":"1024_CR67","unstructured":"ICH guideline impurities in new drug products Q3B(R2). 2006;"},{"key":"1024_CR68","unstructured":"EMA. ICH guideline Q3C (R6) on impurities: guideline for residual solvents. 2019;"},{"key":"1024_CR69","doi-asserted-by":"crossref","unstructured":"Halamoda-Kenzaoui B, Box H, van Elk M, Gaitan S, Geertsma RE, Gainza Lafuente E, et al. Anticipation of regulatory needs for nanotechnology-enabled health products\u2014the REFINE White Paper. Publ Off Eur Union. 2019;EUR 29919.","DOI":"10.33218\/001c.13521"},{"key":"1024_CR70","unstructured":"Karen Zink McCullough. Calculating endotoxin limits for drug products. Am Pharm Rev. 2018; https:\/\/www.americanpharmaceuticalreview.com\/Featured-Articles\/353977-Calculating-Endotoxin-Limits-for-Drug-Products\/"},{"key":"1024_CR71","unstructured":"ICH guideline assessment and control of dna reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7(R1) Current Step 4 version. 2017."},{"key":"1024_CR72","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.phrs.2011.01.006","volume":"63","author":"V Fabiano","year":"2011","unstructured":"Fabiano V, Mameli C, Zuccotti GV. Paediatric pharmacology: remember the excipients. Pharmacol Res. 2011;63:362\u20135. https:\/\/doi.org\/10.1016\/j.phrs.2011.01.006.","journal-title":"Pharmacol Res"},{"key":"1024_CR73","unstructured":"FDA. Inactive ingredients in approved drug products search: frequently asked questions | FDA. [accessed 2021 Mar 4]; https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/inactive-ingredients-approved-drug-products-search-frequently-asked-questions"},{"key":"1024_CR74","doi-asserted-by":"publisher","unstructured":"Grassiri B, Zambito Y, Bernkop-Schn\u00fcrch A. Strategies to prolong the residence time of drug delivery systems on ocular surface. Adv Colloid Interface Sci. 2021;288:1023\u201342. https:\/\/doi.org\/10.1016\/j.cis.2020.102342","DOI":"10.1016\/j.cis.2020.102342"},{"key":"1024_CR75","doi-asserted-by":"crossref","unstructured":"Ma\u0161kov\u00e1 E, Kubov\u00e1 K, Raimi-Abraham BT, Vllasaliu D, Vohl\u00eddalov\u00e1 E, Tur\u00e1nek J, et al. Hypromellose\u2014a traditional pharmaceutical excipient with modern applications in oral and oromucosal drug delivery. J Control Release. 2020;324:695\u2013727. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920303229","DOI":"10.1016\/j.jconrel.2020.05.045"},{"key":"1024_CR76","doi-asserted-by":"crossref","unstructured":"Asim MH, Ijaz M, Mahmood A, Knoll P, Jalil A, Arshad S, et al. Thiolated cyclodextrins: mucoadhesive and permeation enhancing excipients for ocular drug delivery. Int J Pharm. 2021;599:120451. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517321002568","DOI":"10.1016\/j.ijpharm.2021.120451"},{"key":"1024_CR77","doi-asserted-by":"crossref","unstructured":"Kurakula M, Rao GSNK. Pharmaceutical assessment of polyvinylpyrrolidone (PVP): as excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition. J Drug Deliv Sci Technol. 2020;60:102046. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1773224720313356","DOI":"10.1016\/j.jddst.2020.102046"},{"key":"1024_CR78","doi-asserted-by":"crossref","unstructured":"Dahlgren D, Sj\u00f6blom M, Lennern\u00e4s H. Intestinal absorption-modifying excipients: a current update on preclinical in vivo evaluations. Eur J Pharm Biopharm. 2019;142:411\u201320. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641119302516","DOI":"10.1016\/j.ejpb.2019.07.013"},{"key":"1024_CR79","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejpb.2012.09.014","volume":"83","author":"Z Wei","year":"2013","unstructured":"Wei Z, Yuan S, Hao J, Fang X. Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123\/F127 block copolymers: relationship between copolymer concentration and inhibitory activity. Eur J Pharm Biopharm. 2013;83:266\u201374. https:\/\/doi.org\/10.1016\/j.ejpb.2012.09.014.","journal-title":"Eur J Pharm Biopharm Elsevier"},{"key":"1024_CR80","doi-asserted-by":"publisher","unstructured":"Karolewicz B. A review of polymers as multifunctional excipients in drug dosage form technology. Saudi Pharm J. 2016;24:525\u201336. https:\/\/doi.org\/10.1016\/j.jsps.2015.02.025","DOI":"10.1016\/j.jsps.2015.02.025"},{"key":"1024_CR81","doi-asserted-by":"publisher","unstructured":"Eaton MAW, Levy L, Fontaine OMA. Delivering nanomedicines to patients: a practical guide. Nanomedicine Nanotechnology, Biol Med. 2015;11:983\u201392. https:\/\/doi.org\/10.1016\/j.nano.2015.02.004","DOI":"10.1016\/j.nano.2015.02.004"},{"key":"1024_CR82","doi-asserted-by":"publisher","unstructured":"Paliwal R, Babu RJ, Palakurthi S. Nanomedicine scale-up technologies: feasibilities and challenges. AAPS PharmSciTech. 2014;15:1527\u201334. https:\/\/doi.org\/10.1208\/s12249-014-0177-9","DOI":"10.1208\/s12249-014-0177-9"},{"key":"1024_CR83","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejpb.2019.07.013","volume":"142","author":"D Dahlgren","year":"2019","unstructured":"Dahlgren D, Sj\u00f6blom M, Lennern\u00e4s H. Intestinal absorption-modifying excipients: a current update on preclinical in vivo evaluations. Eur J Pharm Biopharm. 2019;142:411\u201320. https:\/\/doi.org\/10.1016\/j.ejpb.2019.07.013.","journal-title":"Eur J Pharm Biopharm"},{"key":"1024_CR84","doi-asserted-by":"publisher","unstructured":"Jarvis B. Good manufacturing practice. Encycl Food Microbiol. 2014. p. 106\u201315. https:\/\/doi.org\/10.1016\/B978-0-12-384730-0.00149-X","DOI":"10.1016\/B978-0-12-384730-0.00149-X"},{"key":"1024_CR85","unstructured":"The Nanomedicine Translation Hub | ETPN. [accessed 2021 Apr 6]; https:\/\/etp-nanomedicine.eu\/about-etpn\/nanomedicine-translation-hub\/"},{"key":"1024_CR86","doi-asserted-by":"publisher","unstructured":"Souto EB, Silva GF, Dias-Ferreira J, Zielinska A, Ventura F, Durazzo A, et al. Nanopharmaceutics: part I\u2014clinical trials legislation and good manufacturing practices (GMP) of nanotherapeutics in the EU. Pharmaceutics. 2020;12. https:\/\/doi.org\/10.3390\/pharmaceutics12020146","DOI":"10.3390\/pharmaceutics12020146"},{"key":"1024_CR87","doi-asserted-by":"publisher","unstructured":"Martins JP, das Neves J, de la Fuente M, Celia C, Florindo H, G\u00fcnday-T\u00fcreli N, et al. The solid progress of nanomedicine. Drug Deliv Transl Res. 2020;10:726\u20139. https:\/\/doi.org\/10.1007\/s13346-020-00743-2","DOI":"10.1007\/s13346-020-00743-2"},{"key":"1024_CR88","doi-asserted-by":"crossref","unstructured":"Colombo S, Beck-Broichsitter M, B\u00f8tker JP, Malmsten M, Rantanen J, Bohr A. Transforming nanomedicine manufacturing toward Quality by Design and microfluidics. Adv Drug Deliv Rev. 2018;128:115\u201331. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X18300565","DOI":"10.1016\/j.addr.2018.04.004"},{"key":"1024_CR89","doi-asserted-by":"crossref","unstructured":"Shegokar R. What nanocrystals can offer to cosmetic and dermal formulations. Nanobiomaterials Galen Formul Cosmet. Elsevier; 2016. p. 69\u201391.","DOI":"10.1016\/B978-0-323-42868-2.00004-8"},{"key":"1024_CR90","doi-asserted-by":"crossref","unstructured":"Shegokar R. Wet media milling: an effective way to solve drug solubility issue. Handb Nanoparticles. Cham: Springer International Publishing; 2016. p. 385\u2013406.","DOI":"10.1007\/978-3-319-15338-4_20"},{"key":"1024_CR91","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijpharm.2010.07.044","volume":"399","author":"R Shegokar","year":"2010","unstructured":"Shegokar R, M\u00fcller RH. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399:129\u201339. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.07.044.","journal-title":"Int J Pharm"},{"key":"1024_CR92","doi-asserted-by":"publisher","unstructured":"Vivek K P, Yuvraj S, Jaya G M, Siddharth G, Manish K C. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. J Control Release. 2014;183:51-66.\u00a0https:\/\/doi.org\/10.1016\/j.jconrel.2014.03.030","DOI":"10.1016\/j.jconrel.2014.03.030"},{"key":"1024_CR93","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20\u201337. https:\/\/doi.org\/10.1038\/nrc.2016.108.","journal-title":"Nat Rev Cancer Nature Publishing Group"},{"key":"1024_CR94","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1172\/JCI66895","volume":"123","author":"SW Jones","year":"2013","unstructured":"Jones SW, Roberts RA, Robbins GR, Perry JL, Kai MP, Chen K, et al. Nanoparticle clearance is governed by Th1\/Th2 immunity and strain background. J Clin Invest. 2013;123:3061\u201373. https:\/\/doi.org\/10.1172\/JCI66895.","journal-title":"J Clin Invest J Clin Invest"},{"key":"1024_CR95","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.addr.2018.04.004","volume":"128","author":"S Colombo","year":"2018","unstructured":"Colombo S, Beck-Broichsitter M, B\u00f8tker JP, Malmsten M, Rantanen J, Bohr A. Transforming nanomedicine manufacturing toward quality by design and microfluidics. Adv Drug Deliv Rev. 2018;128:115\u201331. https:\/\/doi.org\/10.1016\/j.addr.2018.04.004.","journal-title":"Adv Drug Deliv Rev"},{"key":"1024_CR96","unstructured":"Nejat Duzgunes. Liposomes. 2003."},{"key":"1024_CR97","unstructured":"J.C. Leroux, E. Allemann, E. Doelker RG. New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur J Pharm Biopharm. 1995;41:14\u20138."},{"key":"1024_CR98","doi-asserted-by":"publisher","unstructured":"Tao A, Huang G Lo, Igarashi K, Hong T, Liao S, Stellacci F, et al. Polymeric micelles loading proteins through concurrent ion complexation and pH\u2010cleavable covalent bonding for in vivo delivery. Macromol Biosci. 2020;20:1900161. https:\/\/doi.org\/10.1002\/mabi.201900161","DOI":"10.1002\/mabi.201900161"},{"key":"1024_CR99","doi-asserted-by":"publisher","unstructured":"Duro-Castano A, Nebot VJ, Ni\u00f1o-Pariente A, Armi\u00f1\u00e1n A, Arroyo-Crespo JJ, Paul A, et al. Capturing \u201cextraordinary\u201d soft-assembled charge-like polypeptides as a strategy for nanocarrier design. Adv Mater. 2017;29:1702888. https:\/\/doi.org\/10.1002\/adma.201702888","DOI":"10.1002\/adma.201702888"},{"key":"1024_CR100","doi-asserted-by":"publisher","unstructured":"Melnyk T, \u0110or\u0111evi\u0107 S, Conejos-S\u00e1nchez I, Vicent MJ. Therapeutic potential of polypeptide-based conjugates: rational design and analytical tools that can boost clinical translation. Adv Drug Deliv Rev.; 2020;160:136\u201369. https:\/\/doi.org\/10.1016\/j.addr.2020.10.007","DOI":"10.1016\/j.addr.2020.10.007"},{"key":"1024_CR101","unstructured":"Challenges in the manufacture of antibody drug conjugates [Internet]. http:\/\/www.iptonline.com\/articles\/public\/p10-12 non-print.pdf"},{"key":"1024_CR102","doi-asserted-by":"publisher","unstructured":"Hafner A, Lovri\u0107 J, Lak\u01d2 GP, Pepi\u0107 I. Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine. 2014;9:1005\u201323. https:\/\/doi.org\/10.2147\/IJN.S55359","DOI":"10.2147\/IJN.S55359"},{"key":"1024_CR103","doi-asserted-by":"publisher","unstructured":"Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27:26\u201334. https:\/\/doi.org\/10.1038\/nbt0109-26","DOI":"10.1038\/nbt0109-26"},{"key":"1024_CR104","doi-asserted-by":"publisher","unstructured":"Martins S, Tho I, Souto E, Ferreira D, Brandl M. Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles. Eur J Pharm Sci. 2012;45:613\u201323. https:\/\/doi.org\/10.1016\/j.ejps.2011.12.015","DOI":"10.1016\/j.ejps.2011.12.015"},{"key":"1024_CR105","unstructured":"Guidance for industry PAT\u2014a framework for innovative pharmaceutical development, manufacturing, and Quality Assurance. 2004 [accessed 2021 Mar 29]; http:\/\/www.fda.gov\/cvm\/guidance\/published.html"},{"key":"1024_CR106","unstructured":"FDA. Pharmaceutical cGMPs for the 21s Century\u2014a risk-based approach. 2004; http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/Manufacturing\/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs\/UCM071836"},{"key":"1024_CR107","doi-asserted-by":"publisher","unstructured":"Gnoth S, Jenzsch M, Simutis R, L\u00fcbbert A. Process analytical technology (PAT): batch-to-batch reproducibility of fermentation processes by robust process operational design and control. J Biotechnol. 2007;132:180\u20136. https:\/\/doi.org\/10.1016\/j.jbiotec.2007.03.020","DOI":"10.1016\/j.jbiotec.2007.03.020"},{"key":"1024_CR108","doi-asserted-by":"publisher","unstructured":"Read EK, Shah RB, Riley BS, Park JT, Brorson KA, Rathore AS. Process analytical technology (PAT) for biopharmaceutical products: part II. Concepts and applications. Biotechnol Bioeng. 2010;105:285\u201395. https:\/\/doi.org\/10.1002\/bit.22529","DOI":"10.1002\/bit.22529"},{"key":"1024_CR109","doi-asserted-by":"publisher","unstructured":"Bastogne T. Quality-by-design of nanopharmaceuticals\u2014a state of the art. Nanomedicine: Nanotechnol Biol Med. 2017;13:2151\u20137. https:\/\/doi.org\/10.1016\/j.nano.2017.05.014","DOI":"10.1016\/j.nano.2017.05.014"},{"key":"1024_CR110","doi-asserted-by":"publisher","unstructured":"Elliott P, Billingham S, Bi J, Zhang H. Quality by design for biopharmaceuticals: a historical review and guide for implementation. Pharm Bioprocess. 2013;1:105\u201322. https:\/\/doi.org\/10.4155\/pbp.13.6","DOI":"10.4155\/pbp.13.6"},{"key":"1024_CR111","doi-asserted-by":"publisher","unstructured":"Tirand L, Bastogne T, Bechet D, Linder M, Thomas N, Frochot C, et al. Response surface methodology: an extensive potential to optimize in vivo photodynamic therapy conditions. Int J Radiat Oncol Biol Phys. 2009;75:244\u201352. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.04.004","DOI":"10.1016\/j.ijrobp.2009.04.004"},{"key":"1024_CR112","doi-asserted-by":"publisher","unstructured":"Pernot M, Barry NPE, Bastogne T, Frochot C, Barberi-Heyob M, Therrien B. Rational design of an arene ruthenium chlorin conjugate for in vivo anticancer activity. Inorganica Chim Acta. 2014;414:134\u201340. https:\/\/doi.org\/10.1016\/j.ica.2014.01.048","DOI":"10.1016\/j.ica.2014.01.048"},{"key":"1024_CR113","doi-asserted-by":"publisher","unstructured":"Leardi R. Experimental design in chemistry: a tutorial. Anal Chim Acta. 2009;652:161\u201372. https:\/\/doi.org\/10.1016\/j.aca.2009.06.015","DOI":"10.1016\/j.aca.2009.06.015"},{"key":"1024_CR114","doi-asserted-by":"crossref","unstructured":"Miller JN, Miller JC. Chemometrics for analytical chemistry. 2005.","DOI":"10.1002\/9780470988459.ch8"},{"key":"1024_CR115","unstructured":"Home | Nanotechnology Characterization Lab (NCL). [accessed 2021 Mar 24]; https:\/\/nanolab.cancer.gov\/"},{"key":"1024_CR116","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Guidance for industry on drug products, including biological products, that contain nanomaterials. FDA. 2017;Stability studies on rFVIIIFc drug substance. 1\u201314."},{"key":"1024_CR117","doi-asserted-by":"publisher","unstructured":"Halamoda-Kenzaoui B, Ceridono M, Colpo P, Valsesia A, Urb\u00e1n P, Ojea-Jim\u00e9nez I, et al. Dispersion behaviour of silica nanoparticles in biological media and its influence on cellular uptake. PLoS One. 2015;10:e0141593. https:\/\/doi.org\/10.1371\/journal.pone.0141593","DOI":"10.1371\/journal.pone.0141593"},{"key":"1024_CR118","unstructured":"European Medicines Agency. Joint MHLW\/EMA reflection paper on the development of block copolymer micelle medicinal products. EMA\/CHMP\/13099\/2013. 2013;1\u201313. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-joint-ministry-health-labour-welfare\/european-medicines-agency-reflection-paper-development-block-copolymer-micelle-medicinal-products_en.pdf"},{"key":"1024_CR119","unstructured":"European Medicine Agency. Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. EMA\/Committee Hum Med Prod 806058\/2009\/Rev 02. 2013;44:1\u201313. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-data-requirements-intravenous-liposomal-products-developed-reference-innovator_en.pdf"},{"key":"1024_CR120","unstructured":"European Medicine Agency. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed. EMA\/CHMP\/SWP\/620008\/2012. 2015;1\u201311. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-data-requirements-intravenous-iron-based-nano-colloidal-products-developed_en.pdf"},{"key":"1024_CR121","unstructured":"International Standards Organization. ISO\/TR 18196:2016 - Nanotechnologies\u2014measurement technique matrix for the characterization of nano-objects. 2016."},{"key":"1024_CR122","doi-asserted-by":"publisher","unstructured":"Gao X, Lowry G V. Progress towards standardized and validated characterizations for measuring physicochemical properties of manufactured nanomaterials relevant to nano health and safety risks. NanoImpact. 2018;9:14\u201330. https:\/\/doi.org\/10.1016\/j.impact.2017.09.002","DOI":"10.1016\/j.impact.2017.09.002"},{"key":"1024_CR123","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.2174\/1381612822666151216152143","volume":"22","author":"A Ni\u00f1o-pariente","year":"2016","unstructured":"Ni\u00f1o-pariente A, Nebot VJ, Vicent MJ, Vicent MJ. Relevant physicochemical descriptors of \u201csoft nanomedicines\u201d to bypass biological barriers. Curr Pharm Des. 2016;22:1274\u201391. https:\/\/doi.org\/10.2174\/1381612822666151216152143.","journal-title":"Curr Pharm Des"},{"key":"1024_CR124","doi-asserted-by":"publisher","unstructured":"Coty JB, Vauthier C. Characterization of nanomedicines: a reflection on a field under construction needed for clinical translation success. J Control Release.; 2018;275:254\u201368. https:\/\/doi.org\/10.1016\/j.jconrel.2018.02.013","DOI":"10.1016\/j.jconrel.2018.02.013"},{"key":"1024_CR125","doi-asserted-by":"publisher","unstructured":"Caputo F, Clogston J, Calzolai L, R\u00f6sslein M, Prina-Mello A. Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity. J Control Release. 2019;299:31\u201343. https:\/\/doi.org\/10.1016\/j.jconrel.2019.02.030","DOI":"10.1016\/j.jconrel.2019.02.030"},{"key":"1024_CR126","doi-asserted-by":"publisher","unstructured":"Caputo F, Mehn D, Clogston JD, R\u00f6sslein M, Prina-Mello A, Borgos SE, et al. Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals. The joint view of European Union Nanomedicine Characterization Laboratory and National Cancer Institute - Nanotechnology Character. J Chromatogr A. 2021;1635. https:\/\/doi.org\/10.1016\/j.chroma.2020.461767","DOI":"10.1016\/j.chroma.2020.461767"},{"key":"1024_CR127","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2217\/nnm-2017-0338","volume":"13","author":"S Gioria","year":"2018","unstructured":"Gioria S, Caputo F, Urb\u00e1n P, Maguire CM, Bremer-Hoffmann S, Prina-Mello A, et al. Are existing standard methods suitable for the evaluation of nanomedicines: Some case studies. Nanomedicine. 2018;13:539\u201354. https:\/\/doi.org\/10.2217\/nnm-2017-0338.","journal-title":"Nanomedicine"},{"key":"1024_CR128","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nmat2344","volume":"8","author":"S Mitragotri","year":"2009","unstructured":"Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat Mater. 2009;8:15\u201323. https:\/\/doi.org\/10.1038\/nmat2344.","journal-title":"Nat Mater Nature Publishing Group"},{"key":"1024_CR129","doi-asserted-by":"publisher","unstructured":"Zagorodko O, Arroyo-Crespo JJ, Nebot VJ, Vicent MJ. Polypeptide-based conjugates as therapeutics: opportunities and challenges. Macromol Biosci. 2017;17. https:\/\/doi.org\/10.1002\/mabi.201600316","DOI":"10.1002\/mabi.201600316"},{"key":"1024_CR130","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nnano.2017.67","volume":"12","author":"SR D\u2019Mello","year":"2017","unstructured":"D\u2019Mello SR, Cruz CN, Chen ML, Kapoor M, Lee SL, Tyner KM. The evolving landscape of drug products containing nanomaterials in the United States. Nat Nanotechnol. 2017;12:523\u20139. https:\/\/doi.org\/10.1038\/nnano.2017.67.","journal-title":"Nat Nanotechnol Nature Publishing Group"},{"key":"1024_CR131","unstructured":"ICH Official web site\u202f: ICH. [accessed 2021 Mar 25]; https:\/\/www.ich.org\/page\/safety-guidelines"},{"key":"1024_CR132","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Q1A(R2) guideline for stability testing of new drug substances and products. 2003."},{"key":"1024_CR133","doi-asserted-by":"publisher","unstructured":"Hu Y, Crist RM, Clogston JD. The utility of asymmetric flow field-flow fractionation for preclinical characterization of nanomedicines. Anal Bioanal Chem.; 2020;412:425\u201338. https:\/\/doi.org\/10.1007\/s00216-019-02252-9","DOI":"10.1007\/s00216-019-02252-9"},{"key":"1024_CR134","doi-asserted-by":"publisher","unstructured":"Alberg I, Kramer S, Schinnerer M, Hu Q, Seidl C, Leps C, et al. Polymeric nanoparticles with neglectable protein corona. Small. 2020;16. https:\/\/doi.org\/10.1002\/smll.201907574","DOI":"10.1002\/smll.201907574"},{"key":"1024_CR135","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11095-011-0555-x","volume":"29","author":"T Miller","year":"2012","unstructured":"Miller T, Rachel R, Besheer A, Uezguen S, Weigandt M, Goepferich A. Comparative investigations on in vitro serum stability of polymeric micelle formulations. Pharm Res Pharm Res. 2012;29:448\u201359. https:\/\/doi.org\/10.1007\/s11095-011-0555-x.","journal-title":"Pharm Res Pharm Res"},{"key":"1024_CR136","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae - The first FDA-approved nano-drug: lessons learned. J Control Release J Control Release. 2012;160:117\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020.","journal-title":"J Control Release J Control Release"},{"key":"1024_CR137","doi-asserted-by":"publisher","unstructured":"Delmas T, Couffin AC, Bayle PA, Cr\u00e9cy F de, Neumann E, Vinet F, et al. Preparation and characterization of highly stable lipid nanoparticles with amorphous core of tuneable viscosity. J Colloid Interface Sci. J Colloid Interface Sci; 2011;360:471\u201381. https:\/\/doi.org\/10.1016\/j.jcis.2011.04.080","DOI":"10.1016\/j.jcis.2011.04.080"},{"key":"1024_CR138","unstructured":"Mehn D, Caputo F, Roesslein M. EU-NCL protocol: FFF-MALS method development and measurements of size and molecular weight [Internet]. 2016. http:\/\/www.euncl.eu\/about-us\/assay-cascade\/PDFs\/PCC\/EUNCL-PCC-022.pdf?m=1468937868"},{"key":"1024_CR139","doi-asserted-by":"publisher","unstructured":"Hadjidemetriou M, Al-ahmady Z, Buggio M, Swift J, Kostarelos K. A novel scavenging tool for cancer biomarker discovery based on the blood-circulating nanoparticle protein corona. Biomaterials. 2019;188:118\u201329. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.10.011","DOI":"10.1016\/j.biomaterials.2018.10.011"},{"key":"1024_CR140","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nnano.2017.61","volume":"12","author":"M Hadjidemetriou","year":"2017","unstructured":"Hadjidemetriou M, Kostarelos K. Nanomedicine: evolution of the nanoparticle corona. Nat Nanotechnol. 2017;12:288\u201390. https:\/\/doi.org\/10.1038\/nnano.2017.61.","journal-title":"Nat Nanotechnol Nature Publishing Group"},{"key":"1024_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-20884-9","volume":"12","author":"S Sheibani","year":"2021","unstructured":"Sheibani S, Basu K, Farnudi A, Ashkarran A, Ichikawa M, Presley JF, et al. Nanoscale characterization of the biomolecular corona by cryo-electron microscopy, cryo-electron tomography, and image simulation. Nat Commun Nature Research. 2021;12:1\u20139. https:\/\/doi.org\/10.1038\/s41467-020-20884-9.","journal-title":"Nat Commun Nature Research"},{"key":"1024_CR142","doi-asserted-by":"publisher","unstructured":"Mahmoudi M, Moore A. Implications of biomolecular corona for molecular imaging. Mol Imaging Biol. Springer Science and Business Media Deutschland GmbH; 2021;23:1\u201310. https:\/\/doi.org\/10.1007\/s11307-020-01559-9","DOI":"10.1007\/s11307-020-01559-9"},{"key":"1024_CR143","doi-asserted-by":"publisher","unstructured":"Papafilippou L, Claxton A, Dark P, Kostarelos K, Hadjidemetriou M. Protein corona fingerprinting to differentiate sepsis from non-infectious systemic inflammation. Nanoscale; 2020;12:10240\u201353. https:\/\/doi.org\/10.1039\/d0nr02788j","DOI":"10.1039\/d0nr02788j"},{"key":"1024_CR144","doi-asserted-by":"publisher","unstructured":"Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002;46:828\u201333. https:\/\/doi.org\/10.1128\/AAC.46.3.828-833.2002","DOI":"10.1128\/AAC.46.3.828-833.2002"},{"key":"1024_CR145","doi-asserted-by":"publisher","unstructured":"Skoczen S, McNeil SE, Stern ST. Stable isotope method to measure drug release from nanomedicines. J Control Release.; 2015;220:169\u201374. https:\/\/doi.org\/10.1016\/j.jconrel.2015.10.042","DOI":"10.1016\/j.jconrel.2015.10.042"},{"key":"1024_CR146","unstructured":"U.S. Food and Drug Administration. [accessed 2021 Mar 25]; https:\/\/www.fda.gov\/"},{"key":"1024_CR147","doi-asserted-by":"publisher","unstructured":"Ait-Oudhia S, Mager DE, Straubinger RM. Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology. Pharmaceutics; 2014;6:137\u201374. https:\/\/doi.org\/10.3390\/pharmaceutics6010137","DOI":"10.3390\/pharmaceutics6010137"},{"key":"1024_CR148","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jconrel.2011.12.021","volume":"161","author":"E Markovsky","year":"2012","unstructured":"Markovsky E, Baabur-Cohen H, Eldar-Boock A, Omer L, Tiram G, Ferber S, et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release. 2012;161:446\u201360. https:\/\/doi.org\/10.1016\/j.jconrel.2011.12.021.","journal-title":"J Control Release"},{"key":"1024_CR149","doi-asserted-by":"publisher","unstructured":"Finch G, Havel H, Analoui M, Barton RW, Diwan AR, Hennessy M, et al. Nanomedicine drug development: a scientific symposium entitled \u201cCharting a roadmap to commercialization.\u201d AAPS J. 2014;16:698\u2013704. https:\/\/doi.org\/10.1208\/s12248-014-9608-5","DOI":"10.1208\/s12248-014-9608-5"},{"key":"1024_CR150","doi-asserted-by":"publisher","unstructured":"Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm.; 2008;5:505\u201315. https:\/\/doi.org\/10.1021\/mp800051m","DOI":"10.1021\/mp800051m"},{"key":"1024_CR151","doi-asserted-by":"publisher","unstructured":"Chu KS, Hasan W, Rawal S, Walsh MD, Enlow EM, Luft JC, et al. Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine: Nanotechnol. Biol Med.; 2013;9:686\u201393. https:\/\/doi.org\/10.1016\/j.nano.2012.11.008","DOI":"10.1016\/j.nano.2012.11.008"},{"key":"1024_CR152","doi-asserted-by":"publisher","unstructured":"Dobrovolskaia MA. Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy. J Control Release.; 2015;220:571\u201383. https:\/\/doi.org\/10.1016\/j.jconrel.2015.08.056","DOI":"10.1016\/j.jconrel.2015.08.056"},{"key":"1024_CR153","doi-asserted-by":"publisher","unstructured":"Shaffer SA, Baker-Lee C, Kennedy J, Lai MS, De Vries P, Buhler K, et al. In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother Pharmacol.; 2007;59:537\u201348. https:\/\/doi.org\/10.1007\/s00280-006-0296-4","DOI":"10.1007\/s00280-006-0296-4"},{"key":"1024_CR154","doi-asserted-by":"publisher","unstructured":"Han L, Zhan H, Sun X, Zhang ZR, Deng L. A density-changing centrifugation method for efficient separation of free drugs from drug-loaded particulate delivery systems. AAPS J. ; 2019;21:1\u201311. https:\/\/doi.org\/10.1208\/s12248-019-0306-1","DOI":"10.1208\/s12248-019-0306-1"},{"key":"1024_CR155","doi-asserted-by":"publisher","unstructured":"Edwards KA, Baeumner AJ. Analysis of liposomes. Talanta; 2006;68:1432\u201341. https:\/\/doi.org\/10.1016\/j.talanta.2005.08.031","DOI":"10.1016\/j.talanta.2005.08.031"},{"key":"1024_CR156","doi-asserted-by":"publisher","unstructured":"G\u00f3mez-Hens A, Fern\u00e1ndez-Romero JM. Analytical methods for the control of liposomal delivery systems. TrAC\u2014Trends Anal Chem.; 2006;25:167\u201378. https:\/\/doi.org\/10.1016\/j.trac.2005.07.006","DOI":"10.1016\/j.trac.2005.07.006"},{"key":"1024_CR157","doi-asserted-by":"publisher","unstructured":"Chimanuka B, Gabri\u00ebls M, Detaevernier MR, Plaizier-Vercammen JA. Preparation of \u03b2-artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice. J Pharm Biomed Anal.; 2002;28:13\u201322. https:\/\/doi.org\/10.1016\/S0731-7085(01)00611-2","DOI":"10.1016\/S0731-7085(01)00611-2"},{"key":"1024_CR158","doi-asserted-by":"publisher","unstructured":"Wu PC, Tsai YH, Liao CC, Chang JS, Huang Y Bin. The characterization and biodistribution of cefoxitin-loaded liposomes. Int J Pharm.; 2004;271:31\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2003.10.034","DOI":"10.1016\/j.ijpharm.2003.10.034"},{"key":"1024_CR159","doi-asserted-by":"publisher","unstructured":"Junping W, Maitani Y, Takayama K, Nagai T. In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome. Int J Pharm.; 2000;203:61\u20139. https:\/\/doi.org\/10.1016\/S0378-5173(00)00410-5","DOI":"10.1016\/S0378-5173(00)00410-5"},{"key":"1024_CR160","doi-asserted-by":"publisher","unstructured":"Bellott R, Pouna P, Robert J. Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome. J Chromatogr B Biomed Sci Appl.; 2001;757:257\u201367. https:\/\/doi.org\/10.1016\/S0378-4347(01)00151-7","DOI":"10.1016\/S0378-4347(01)00151-7"},{"key":"1024_CR161","doi-asserted-by":"publisher","unstructured":"Mehn D, Iavicoli P, Cabaleiro N, Borgos SE, Caputo F, Geiss O, et al. Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes. Int J Pharm.; 2017;523:320\u20136. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.03.046","DOI":"10.1016\/j.ijpharm.2017.03.046"},{"key":"1024_CR162","doi-asserted-by":"publisher","unstructured":"Skoczen SL, Stern ST. Improved ultrafiltration method to measure drug release from nanomedicines utilizing a stable isotope tracer. Methods Mol Biol.; 2018. p. 223\u201339. https:\/\/doi.org\/10.1007\/978-1-4939-7352-1_19","DOI":"10.1007\/978-1-4939-7352-1_19"},{"key":"1024_CR163","doi-asserted-by":"publisher","unstructured":"Hauschke D, Steinijans V, Pigeot I. Bioequivalence Studies in Drug Development [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2007. https:\/\/doi.org\/10.1002\/9780470094778","DOI":"10.1002\/9780470094778"},{"key":"1024_CR164","unstructured":"Closing The gap for generic nanomedicines [Internet]. https:\/\/cen.acs.org\/articles\/92\/i45\/Closing-Gap-Generic-Nanomedicines.html"},{"key":"1024_CR165","doi-asserted-by":"publisher","unstructured":"Clogston JD, Crist RM, McNeil SE. Physicochemical characterization of polymer nanoparticles: challenges and present limitations. Polym Nanoparticles Nanomedicines. Springer International Publishing; 2016. p. 187\u2013203. https:\/\/doi.org\/10.1007\/978-3-319-41421-8_7","DOI":"10.1007\/978-3-319-41421-8_7"},{"key":"1024_CR166","doi-asserted-by":"publisher","unstructured":"Clogston JD, Patri AK. Importance of physicochemical characterization prior to immunological studies. Handb Immunol Prop Eng Nanomater. 2013. p. 25\u201352. https:\/\/doi.org\/10.1142\/9789814390262_0002","DOI":"10.1142\/9789814390262_0002"},{"key":"1024_CR167","doi-asserted-by":"publisher","unstructured":"McNeil SE. Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology.; 2009;1:264\u201371. https:\/\/doi.org\/10.1002\/wnan.6","DOI":"10.1002\/wnan.6"},{"key":"1024_CR168","doi-asserted-by":"publisher","unstructured":"Ragelle H, Danhier F, Pr\u00e9at V, Langer R, Anderson DG. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opin Drug Deliv.; 2017;14:851\u201364. https:\/\/doi.org\/10.1080\/17425247.2016.1244187","DOI":"10.1080\/17425247.2016.1244187"},{"key":"1024_CR169","unstructured":"Assay Cascade, EU-NCL. [accessed 2021 Apr 6]; http:\/\/www.euncl.eu\/about-us\/assay-cascade\/"},{"key":"1024_CR170","unstructured":"Assay Cascade Protocols | Nanotechnology Characterization Lab (NCL). [accessed 2021 Apr 6]; https:\/\/ncl.cancer.gov\/resources\/assay-cascade-protocols"},{"key":"1024_CR171","doi-asserted-by":"publisher","unstructured":"Bremer S, Halamoda-Kenzaoui B, Borgos SE. Identification of regulatory needs for nanomedicines. 1st EU-NCL survey with the \u201cNanomedicine\u201d working group of the international pharmaceutical regulators. JRC. 2016; https:\/\/doi.org\/10.2788\/585950","DOI":"10.2788\/585950"},{"key":"1024_CR172","doi-asserted-by":"publisher","unstructured":"Bavli Y, Chen BM, Roffler SR, Dobrovolskaia MA, Elnekave E, Ash S, et al. PEGylated liposomal methyl prednisolone succinate does not induce infusion reactions in patients: a correlation between in vitro immunological and in vivo clinical studies. Molecules.; 2020;25:558\u201378. https:\/\/doi.org\/10.3390\/molecules25030558","DOI":"10.3390\/molecules25030558"},{"key":"1024_CR173","doi-asserted-by":"publisher","unstructured":"Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138\u201357. https:\/\/doi.org\/10.1016\/j.jconrel.2014.12.030","DOI":"10.1016\/j.jconrel.2014.12.030"},{"key":"1024_CR174","doi-asserted-by":"crossref","unstructured":"Mahmoudi M. Debugging nano\u2013bio interfaces: systematic strategies to accelerate clinical translation of nanotechnologies. Trends Biotechnol. 2018;36:755\u201369. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779918300829","DOI":"10.1016\/j.tibtech.2018.02.014"},{"key":"1024_CR175","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","volume":"10","author":"HH Gustafson","year":"2015","unstructured":"Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H. Nanoparticle uptake: The phagocyte problem. Nano Today. 2015;10:487\u2013510.","journal-title":"Nano Today"},{"key":"1024_CR176","doi-asserted-by":"publisher","unstructured":"Jain K, Shukla R, Yadav A, Ujjwal RR, Flora SJS. 3D printing in development of nanomedicines. Nanomaterials. 2021;11:1\u201324. https:\/\/doi.org\/10.3390\/nano11020420","DOI":"10.3390\/nano11020420"},{"key":"1024_CR177","doi-asserted-by":"publisher","unstructured":"Silvestri A, Vicente F, Vicent MJ, Stechmann B, Fecke W. Academic collaborative models fostering the translation of physiological in vitro systems from basic research into drug discovery. Drug Discov Today.; 2021;\u00a0https:\/\/doi.org\/10.1016\/j.drudis.2021.02.024","DOI":"10.1016\/j.drudis.2021.02.024"},{"key":"1024_CR178","doi-asserted-by":"publisher","unstructured":"Toh YC, Lim TC, Tai D, Xiao G, Van Noort D, Yu H. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip.; 2009;9:2026\u201335. https:\/\/doi.org\/10.1039\/b900912d","DOI":"10.1039\/b900912d"},{"key":"1024_CR179","doi-asserted-by":"publisher","unstructured":"Albanese A, Lam AK, Sykes EA, Rocheleau J V., Chan WCW. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. Nat Commun.; 2013;4. https:\/\/doi.org\/10.1038\/ncomms3718","DOI":"10.1038\/ncomms3718"},{"key":"1024_CR180","doi-asserted-by":"publisher","unstructured":"Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Yuan Hsin H, Ingber DE. Reconstituting organ-level lung functions on a chip. Science (80- ). 2010;328:1662\u20138. https:\/\/doi.org\/10.1126\/science.1188302","DOI":"10.1126\/science.1188302"},{"key":"1024_CR181","doi-asserted-by":"crossref","unstructured":"Boix-Montesinos P, Soriano-Teruel PM, Armi\u00f1\u00e1n de Benito A, Orz\u00e1ez M, Vicent MJ. The past, present, and future of breast cancer models for nanomedicine development. Adv Drug Deliv Rev. 2021; https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X2100096X","DOI":"10.1016\/j.addr.2021.03.018"},{"key":"1024_CR182","doi-asserted-by":"crossref","unstructured":"Ofek P, Tiram G, Satchi-Fainaro R. Angiogenesis regulation by nanocarriers bearing RNA interference. Adv Drug Deliv Rev. 2017;119:3\u201319. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X17300273","DOI":"10.1016\/j.addr.2017.01.008"},{"key":"1024_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.04.001","author":"S Pozzi","year":"2021","unstructured":"Pozzi S, Scomparin A, Israeli-Dangoor S, Rodriguez D, Ofek P, Neufeld L, et al. Meet me halfway: are in vitro 3D cancer models on the way to replace in vivo models for nanomedicine development? Adv Drug Deliv Rev. 2021. https:\/\/doi.org\/10.1016\/j.addr.2021.04.001.","journal-title":"Elsevier"},{"key":"1024_CR184","doi-asserted-by":"crossref","unstructured":"Brancato V, Oliveira JM, Correlo VM, Reis RL, Kundu SC. Could 3D models of cancer enhance drug screening? Biomaterials. 2020;232:119744. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961219308622","DOI":"10.1016\/j.biomaterials.2019.119744"},{"key":"1024_CR185","doi-asserted-by":"publisher","unstructured":"Ma H, Jiang Q, Han S, Wu Y, Tomshine JC, Wang D, et al. Multicellular tumor spheroids as an in vivo\u2013like tumor model for three-dimensional imaging of chemotherapeutic and nano material cellular penetration. Mol Imaging. 2012;11:7290.2012.00012. https:\/\/doi.org\/10.2310\/7290.2012.00012","DOI":"10.2310\/7290.2012.00012"},{"key":"1024_CR186","doi-asserted-by":"publisher","unstructured":"Nunes AS, Barros AS, Costa EC, Moreira AF, Correia IJ. 3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. Biotechnol Bioeng. 2019;116:206\u201326. https:\/\/doi.org\/10.1002\/bit.26845","DOI":"10.1002\/bit.26845"},{"key":"1024_CR187","doi-asserted-by":"publisher","unstructured":"Furxhi I, Murphy F, Mullins M, Arvanitis A, Poland CA. Nanotoxicology data for in silico tools: a literature review. Nanotoxicology.; 2020;14:612\u201337. https:\/\/doi.org\/10.1080\/17435390.2020.1729439","DOI":"10.1080\/17435390.2020.1729439"},{"key":"1024_CR188","doi-asserted-by":"publisher","unstructured":"Choi SYC, Lin D, Gout PW, Collins CC, Xu Y, Wang Y. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv Drug Deliv Rev.; 2014;79:222\u201337. https:\/\/doi.org\/10.1016\/j.addr.2014.09.009","DOI":"10.1016\/j.addr.2014.09.009"},{"key":"1024_CR189","doi-asserted-by":"publisher","unstructured":"Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov. ; 2006;5:741\u201354. https:\/\/doi.org\/10.1038\/nrd2110","DOI":"10.1038\/nrd2110"},{"key":"1024_CR190","doi-asserted-by":"publisher","unstructured":"Boix-Montesinos P, Soriano-Teruel PM, Armi\u00f1\u00e1n de Benito A, Orz\u00e1ez M, Vicent MJ. The past, present, and future of breast cancer models for nanomedicine development. Adv Drug Deliv Rev. 2021; https:\/\/doi.org\/10.1016\/j.addr.2021.03.018","DOI":"10.1016\/j.addr.2021.03.018"},{"key":"1024_CR191","doi-asserted-by":"publisher","unstructured":"Figueir\u00f3 Longo JP, Muehlmann LA. Nanomedicine beyond tumor passive targeting: What next. Nanomedicine.; 2020;15:1819\u201322. https:\/\/doi.org\/10.2217\/nnm-2020-0208","DOI":"10.2217\/nnm-2020-0208"},{"key":"1024_CR192","doi-asserted-by":"publisher","unstructured":"Metselaar JM, Lammers T. Challenges in nanomedicine clinical translation. Drug Deliv Transl Res. 2020;10:721\u20135. https:\/\/doi.org\/10.1007\/s13346-020-00740-5","DOI":"10.1007\/s13346-020-00740-5"},{"key":"1024_CR193","doi-asserted-by":"publisher","unstructured":"Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty S V., Teichmann LL, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014;32:364\u201372. https:\/\/doi.org\/10.1038\/nbt.2858","DOI":"10.1038\/nbt.2858"},{"key":"1024_CR194","doi-asserted-by":"publisher","unstructured":"Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi-Frias D, et al. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Res. 2016;76:283\u201392. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3280","DOI":"10.1158\/0008-5472.CAN-14-3280"},{"key":"1024_CR195","doi-asserted-by":"publisher","unstructured":"Giannaccini M, Cuschieri A, Dente L, Raffa V. Non-mammalian vertebrate embryos as models in nanomedicine. Nanomedicine: Nanotechnol Biol Med. 2014;10:703\u201319. https:\/\/doi.org\/10.1016\/j.nano.2013.09.010","DOI":"10.1016\/j.nano.2013.09.010"},{"key":"1024_CR196","doi-asserted-by":"publisher","unstructured":"Moghimi SM, Simberg D. Translational gaps in animal models of human infusion reactions to nanomedicines. Nanomedicine. 2018;13:973\u20135. https:\/\/doi.org\/10.2217\/nnm-2018-0064","DOI":"10.2217\/nnm-2018-0064"},{"key":"1024_CR197","doi-asserted-by":"publisher","unstructured":"Sieber S, Grossen P, Bussmann J, Campbell F, Kros A, Witzigmann D, et al. Zebrafish as a preclinical in vivo screening model for nanomedicines. Adv Drug Deliv Rev. 2019;151\u2013152:152\u201368. https:\/\/doi.org\/10.1016\/j.addr.2019.01.001","DOI":"10.1016\/j.addr.2019.01.001"},{"key":"1024_CR198","doi-asserted-by":"publisher","unstructured":"Gonzalez-Moragas L, Berto P, Vilches C, Quidant R, Kolovou A, Santarella-Mellwig R, et al. In vivo testing of gold nanoparticles using the Caenorhabditis elegans model organism. Acta Biomater. 2017;53:598\u2013609. https:\/\/doi.org\/10.1016\/j.actbio.2017.01.080","DOI":"10.1016\/j.actbio.2017.01.080"},{"key":"1024_CR199","doi-asserted-by":"crossref","unstructured":"White RM, Sessa A, Burke C, Bowman T, LeBlanc J, Ceol C, et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell. 2008;2:183\u20139. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1934590907002755","DOI":"10.1016\/j.stem.2007.11.002"},{"key":"1024_CR200","doi-asserted-by":"publisher","unstructured":"Tobin DM, Ramakrishnan L. Comparative pathogenesis of Mycobacterium marinum and Mycobacterium tuberculosis. Cell Microbiol. 2008;10:1027\u201339. https:\/\/doi.org\/10.1111\/j.1462-5822.2008.01133.x","DOI":"10.1111\/j.1462-5822.2008.01133.x"},{"key":"1024_CR201","doi-asserted-by":"publisher","unstructured":"Cronan MR, Tobin DM. Fit for consumption: zebrafish as a model for tuberculosis. Dis Model Mech. 2014;7:777\u201384. https:\/\/doi.org\/10.1242\/dmm.016089","DOI":"10.1242\/dmm.016089"},{"key":"1024_CR202","doi-asserted-by":"crossref","unstructured":"Begley CG, Ellis LM. Raise standards for preclinical cancer research. Nature. 2012;483:531\u20133. http:\/\/www.nature.com\/articles\/483531a","DOI":"10.1038\/483531a"},{"key":"1024_CR203","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.bbrc.2015.08.023","volume":"468","author":"V Sainz","year":"2015","unstructured":"Sainz V, Conniot J, Matos AI, Peres C, Zupan\u01d2i\u01d2 E, Moura L, et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015;468:504\u201310.","journal-title":"Biochem Biophys Res Commun"},{"key":"1024_CR204","doi-asserted-by":"publisher","unstructured":"Valcourt DM, Kapadia CH, Scully MA, Dang MN, Day ES. Best practices for preclinical in vivo testing of cancer nanomedicines. Adv Healthc Mater. 2020;9:2000110. https:\/\/doi.org\/10.1002\/adhm.202000110","DOI":"10.1002\/adhm.202000110"},{"key":"1024_CR205","doi-asserted-by":"publisher","unstructured":"Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017;108:25\u201338. https:\/\/doi.org\/10.1016\/j.addr.2016.04.025","DOI":"10.1016\/j.addr.2016.04.025"},{"key":"1024_CR206","doi-asserted-by":"publisher","unstructured":"Havel H, Finch G, Strode P, Wolfgang M, Zale S, Bobe I, et al. Nanomedicines: from bench to bedside and beyond. AAPS J. Springer New York LLC; 2016;18:1373\u20138. https:\/\/doi.org\/10.1208\/s12248-016-9961-7","DOI":"10.1208\/s12248-016-9961-7"},{"key":"1024_CR207","doi-asserted-by":"publisher","unstructured":"Hendriks B, Shields A, Siegel BA, Miller K, Munster P, Ma C, et al. PET\/CT Imaging of 64CU-Labelled HER2 Liposomal Doxorubicin (64CU-MM-302) Quantifies variability of liposomal drug delivery to diverse tumor lesions in HER2-positive breast cancer patients. Ann Oncol. 2014;25:i19. https:\/\/doi.org\/10.1093\/annonc\/mdu068.1","DOI":"10.1093\/annonc\/mdu068.1"},{"key":"1024_CR208","doi-asserted-by":"publisher","unstructured":"Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Abra RM, Stewart JSW. Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: Implications for novel targeting strategies. Br J Cancer. Churchill Livingstone; 2000;83:232\u20138. https:\/\/doi.org\/10.1054\/bjoc.1999.1232","DOI":"10.1054\/bjoc.1999.1232"},{"key":"1024_CR209","doi-asserted-by":"publisher","unstructured":"Ramanathan RK, Korn RL, Sachdev JC, Fetterly GJ, Marceau K, Marsh V, et al. Abstract CT224: Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI). 2014. p. CT224\u2013CT224. https:\/\/doi.org\/10.1158\/1538-7445.am2014-ct224","DOI":"10.1158\/1538-7445.am2014-ct224"},{"key":"1024_CR210","doi-asserted-by":"publisher","unstructured":"Low S, Hoff D Von, Mita M, Burris H, Eisenberg P, Hart L, et al. Abstract 911: Prostate-specific membrane antigen (PSMA) expression as a potential patient selection marker in patients with refractory solid tumors administered BIND-014, a PSMA-targeted nanoparticle containing docetaxel. 2014. p. 911\u2013911. https:\/\/doi.org\/10.1158\/1538-7445.am2014-911","DOI":"10.1158\/1538-7445.am2014-911"},{"key":"1024_CR211","doi-asserted-by":"publisher","unstructured":"van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14:1007\u201317. https:\/\/doi.org\/10.1038\/s41565-019-0567-y","DOI":"10.1038\/s41565-019-0567-y"},{"key":"1024_CR212","doi-asserted-by":"publisher","unstructured":"Gaspar R, Duncan R. Polymeric carriers: Preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev. 2009;61:1220\u201331. https:\/\/doi.org\/10.1016\/j.addr.2009.06.003","DOI":"10.1016\/j.addr.2009.06.003"},{"key":"1024_CR213","doi-asserted-by":"publisher","unstructured":"Dobrovolskaia MA, McNeil SE. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release. 2013;172:456\u201366. https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.025","DOI":"10.1016\/j.jconrel.2013.05.025"},{"key":"1024_CR214","unstructured":"Sadrieh N. Regulatory considerations for nanomaterial-containing therapeutics. 2009 [accessed 2021 Mar 25]; https:\/\/pqri.org\/wp-content\/uploads\/2015\/08\/pdf\/Presentation_Sadrieh.pdf"},{"key":"1024_CR215","doi-asserted-by":"publisher","unstructured":"Crist RM, Grossman JH, Patri AK, Stern ST, Dobrovolskaia MA, Adiseshaiah PP, et al. Common pitfalls in nanotechnology: lessons learned from NCI\u2019s Nanotechnology Characterization Laboratory. Integr Biol (UK). 2013;5:66\u201373. https:\/\/doi.org\/10.1039\/c2ib20117h","DOI":"10.1039\/c2ib20117h"},{"key":"1024_CR216","doi-asserted-by":"publisher","unstructured":"Savage DT, Hilt JZ, Dziubla TD. In vitro methods for assessing nanoparticle toxicity. Methods Mol Biol. 2019. p. 1\u201329. https:\/\/doi.org\/10.1007\/978-1-4939-8916-4_1","DOI":"10.1007\/978-1-4939-8916-4_1"},{"key":"1024_CR217","doi-asserted-by":"publisher","unstructured":"Forest V, Hochepied J-F, Pourchez J. Importance of choosing relevant biological end points to predict nanoparticle toxicity with computational approaches for human health risk assessment. Chem Res Toxicol. 2019;32:1320\u20136. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00022\u00ef","DOI":"10.1021\/acs.chemrestox"},{"key":"1024_CR218","doi-asserted-by":"publisher","unstructured":"Giannakou C, E. Geertsma R, H. de Jong W, van Loveren H, J. Vandebriel R, VDZ Park M. Immunotoxicity testing of nanomedicinal products: possible pitfalls in endotoxin determination. Curr Bionanotechnol. 2016;2:95\u2013102. https:\/\/doi.org\/10.2174\/2213529402666160601115600","DOI":"10.2174\/2213529402666160601115600"},{"key":"1024_CR219","doi-asserted-by":"publisher","unstructured":"Halamoda-Kenzaoui B, Baconnier S, Bastogne T, Bazile D, Boisseau P, Borchard G, et al. Bridging communities in the field of nanomedicine. Regul Toxicol Pharmacol. 2019;106:187\u201396. https:\/\/doi.org\/10.1016\/j.yrtph.2019.04.011","DOI":"10.1016\/j.yrtph.2019.04.011"},{"key":"1024_CR220","doi-asserted-by":"crossref","unstructured":"Fadeel B. Hide and seek: Nanomaterial interactions with the immune system. Front Immunol. Frontiers Media S.A.; 2019;10. https:\/\/pubmed.ncbi.nlm.nih.gov\/30774634\/","DOI":"10.3389\/fimmu.2019.00133"},{"key":"1024_CR221","unstructured":"ICH Topic S 8 Immunotoxicity studies for human pharmaceuticals [Internet]. 2006. http:\/\/www.emea.eu.int"},{"key":"1024_CR222","doi-asserted-by":"publisher","unstructured":"Avila YI, Chandler M, Cedrone E, Newton HS, Richardson M, Xu J, et al. Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the type of delivery carrier. Molecules. 2021;26:652\u201370. https:\/\/doi.org\/10.3390\/molecules26030652","DOI":"10.3390\/molecules26030652"},{"key":"1024_CR223","doi-asserted-by":"publisher","unstructured":"Caron WP, Morgan KP, Zamboni BA, Zamboni WC. A review of study designs and outcomes of phase I clinical studies of nanoparticle agents compared with small-molecule anticancer agents. Clin Cancer Res. 2013;19:3309\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3649","DOI":"10.1158\/1078-0432.CCR-12-3649"},{"key":"1024_CR224","doi-asserted-by":"publisher","unstructured":"Liu Z, Qiu S, Liu Z, Hou L, Li Y, Wang J, et al. Complement activation associated with polysorbate 80 in beagle dogs. Int Immunopharmacol. 2013;15:144\u20139. https:\/\/doi.org\/10.1016\/j.intimp.2012.10.021","DOI":"10.1016\/j.intimp.2012.10.021"},{"key":"1024_CR225","doi-asserted-by":"publisher","unstructured":"Masini E, Planchenault J, Pezziardi F, Gautier P, Gagnol JP. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions. 1985;16:470\u20137. https:\/\/doi.org\/10.1007\/BF01983649","DOI":"10.1007\/BF01983649"},{"key":"1024_CR226","doi-asserted-by":"publisher","unstructured":"Crist RM, Dasa SSK, Liu CH, Clogston JD, Dobrovolskaia MA, Stern ST. Challenges in the development of nanoparticle-based imaging agents: characterization and biology. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology. 2021;13:e1665. https:\/\/doi.org\/10.1002\/wnan.1665","DOI":"10.1002\/wnan.1665"},{"key":"1024_CR227","doi-asserted-by":"publisher","unstructured":"Begley CG, Ellis LM. Raise standards for preclinical cancer research. Nature. 2012;483:531\u20133. https:\/\/doi.org\/10.1038\/483531a","DOI":"10.1038\/483531a"},{"key":"1024_CR228","doi-asserted-by":"crossref","unstructured":"Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10:712\u2013712. http:\/\/www.nature.com\/articles\/nrd3439-c1","DOI":"10.1038\/nrd3439-c1"},{"key":"1024_CR229","doi-asserted-by":"publisher","unstructured":"He H, Liu L, Morin EE, Liu M, Schwendeman A. Survey of clinical translation of cancer nanomedicines\u2014lessons learned from successes and failures. Acc Chem Res. 2019;52:2445\u201361. https:\/\/doi.org\/10.1021\/acs.accounts.9b00228","DOI":"10.1021\/acs.accounts.9b00228"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01024-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-021-01024-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01024-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T11:50:54Z","timestamp":1699271454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-021-01024-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":229,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1007\/s13346-021-01024-2","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"29 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animal experiments. All authors have reviewed and agreed with the content of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed, agreed with the content of the manuscript and consent its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}